Mesoblast Limited, a clinical development company, is engaged in the research and development of its propriety stem cell technologies for use in the treatment of multiple major disease states and other medical conditions. The companys cell-based core technologies include its Mesenchymal Precursor Cell (MPC) technology platform, which is used to develop products derived from bone marrow and adipose tissue sources; Dental Pulp Stem Cells technology; and expanded Hematopoietic Stem Cells technology. It develops products for intravenous administration to target unmet medical needs in diseases of excessive inflammation and immune dysfunction, including type 2 diabetes, inflammatory joint diseases, and inflammatory lung diseases; MPC treatment therapies for diseases of the spine; adult stem cell-based therapies for the treatment of cardiovascular diseases, including congestive heart failure; and products for treating eye diseases, neurologic diseases, and cord blood expansion. The company has strategic alliances with Lonza Group for clinical and long-term commercial production of its off-the-shelf (allogeneic) adult stem cell products; and Teva Pharmaceutical Industries Ltd. for the development and commercialization of its MPC products in various diseases, including cardiovascular diseases and neurologic conditions. It has operations in Australia, the United States, and Singapore. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.